SLGL vs DERM vs PRGO vs SKIN vs VYNE

For growth investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger pick with 68. 0% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Sol-Gel Technologies Ltd. (SLGL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Sol-Gel Technologies Ltd.

(SLGL) delivered a total return of -27. 1%, compared to -99. 0% for VYNE Therapeutics Inc. (VYNE). Over 10 years, the gap is even starker: DERM returned -47. 4% versus VYNE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sol-Gel Technologies Ltd.

(SLGL) is the lower-risk stock at -0. 18β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately -1237% more volatile than SLGL relative to the S&P 500. On balance sheet safety, Sol-Gel Technologies Ltd. (SLGL) carries a lower debt/equity ratio of 4% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sol-Gel Technologies Ltd.

(SLGL) is pulling ahead at 68. 0% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, SLGL leads at 70. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -46. 5% for VYNE Therapeutics Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -52. 2% for VYNE. At the gross margin level — before operating expenses — SLGL leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 69. 0x for Journey Medical Corporation — 63. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

In this comparison, PRGO (9.

8% yield) pays a dividend. SLGL, DERM, SKIN, VYNE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 18)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SLGL: -49. 0%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SLGL (Healthcare) and DERM (Healthcare) and PRGO (Healthcare) and SKIN (Consumer Defensive) and VYNE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SLGL is a small-cap high-growth stock; DERM is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; SKIN is a small-cap quality compounder stock; VYNE is a small-cap quality compounder stock. PRGO pays a dividend while SLGL, DERM, SKIN, VYNE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.